微创机器人-B(02252)再涨超10%，机器人行业再迎热度，公司商业化进程稳健推进。 东阳光药(06887)涨近7%，中期毛利14.68亿元，伊非尼酮关键数据亮相美国IPF峰会。 创胜集团-B(06628)拉升逾28%，中期净亏损同比收窄17.9%，TST001研究数据首次亮相ASCO。 金界控股(03918)涨超6%，上半年业绩超出市场预期，花旗称Naga3项目不确定性仍存。 绿色动力环保(01330)涨超7%，上半年归母净利同比增加24.49%，供汽业务成为业绩增长核心引擎。 汇量科技(01860)涨7.9% ，上半年收入同比大增四成，机构看好Mintegral平台飞轮效应持续释放。 赤子城科技(09911)再涨超6%，上半年纯利增近1.2倍，今年集团毛利率有望同比大幅优化。 四环医药(00460)再涨超7%，上半年实现扭亏为盈，AI+医美战略布局进入实质性阶段。 国富量子(00290)再涨6.86%，年内累计涨幅已近1.8倍，公司携手华检医疗推进RWA生态构建。 新意网集团(01686)绩后跌超17%，全年纯利同比增8%至9.79亿港元。 恒生生物科技指数逆市上扬1%；指数成份股中，微创机器人（022 ...

Core Viewpoint - Huajian Medical (01931) has seen a significant stock increase of over 13% following the announcement of a conditional agreement to acquire a 20.31% stake in Guofu Quantum for approximately HKD 3.142 billion, which will be paid through the issuance of shares. This acquisition aims to enhance capital synergy and establish an innovative cooperative network to support the globalization of Chinese assets [1][2]. Group 1 - Huajian Medical's stock rose by 13.31% to HKD 10.98, with a trading volume of HKD 45.6534 million [1]. - The acquisition of Guofu Quantum will make Huajian Medical the major shareholder, aiming to strengthen capital collaboration and broaden institutional cooperation [1]. - The company has launched several strategic initiatives since late July, including the "NewCo+RWA" exchange strategy and the issuance of IVDD stablecoins [2]. Group 2 - Huajian Medical's U.S. subsidiary is pursuing a stablecoin license, and the company has partnered with BGI's Huada Gongying to establish the world's first "innovative drug intellectual property tokenization fund" [2]. - The company announced the initiation of a "global enhanced Ethereum (ETH) treasury" strategy and completed a compliant purchase of HKD 149 million in ETH [2]. - Huajian Medical is seeking shareholder approval for a HKD 3 billion ETH purchase authorization to support the ecosystem construction of the medical innovative drug RWA trading platform [2].

Group 1 - Huajian Medical (01931) shares rose over 13%, reaching 10.98 HKD with a trading volume of 45.65 million HKD [1] - The company announced a conditional agreement to acquire 20.31% of Guofu Quantum's shares for approximately 3.142 billion HKD, to be paid through the issuance of consideration shares [1] - This acquisition aims to enhance capital synergy, promote the implementation of RWA ecosystem, and build an innovative cooperation network to support the globalization of Chinese assets [1] Group 2 - Since late July, Huajian Medical has launched several key strategic initiatives, including the introduction of the "NewCo+RWA" exchange strategy and the issuance of IVDD stablecoins [2] - The company is pursuing a stablecoin license for its U.S. subsidiary and has partnered with BGI's subsidiary to establish the world's first "innovative drug intellectual property tokenization fund" [2] - On August 8, Huajian Medical initiated the "Global Enhanced Ethereum (ETH) Treasury" strategy, collaborating with licensed exchange HashKey and completing a compliant purchase of 149 million HKD in ETH [2] - The company is seeking shareholder approval for a 3 billion HKD ETH purchase authorization to provide value anchoring and revenue feedback mechanisms for the RWA trading platform [2]

Core Viewpoint - The surge in Huajian Medical's stock price is driven by its announcement to apply for stablecoin issuance licenses in Hong Kong and the U.S., positioning itself as a pioneer in the medical technology sector for stablecoin issuance [2][3][4]. Group 1: Stock Performance - On July 21, Huajian Medical's stock opened significantly higher, peaking at a 58% increase, and closed up 32.88% at HKD 3.92 per share, with a market capitalization of HKD 6.356 billion [2]. - The company experienced a cumulative stock increase of 60% over two days, with trading volume exceeding HKD 50 million [2]. Group 2: Business Developments - On July 17, Huajian Medical announced the initiation of its stablecoin issuance license application process with relevant regulatory bodies in Hong Kong and the U.S. [2][3]. - The company’s U.S. subsidiary, IVDGROUPINC., has completed its registration and is now officially starting the stablecoin license application process [3]. Group 3: Market Reactions and Analysis - The market has shown mixed reactions to Huajian Medical's cross-industry initiatives, with some skepticism regarding its motives and the potential for "storytelling" [3]. - Analysts suggest that the company's approach addresses long-standing issues in the innovative drug sector, such as low liquidity and long financing cycles, by creating a Real World Asset (RWA) exchange focused on medical innovation [3][4]. Group 4: Regulatory Environment - Recent legislative developments in Hong Kong and the U.S. provide a favorable regulatory framework for stablecoin operations, enhancing Huajian Medical's strategic positioning [4]. - The Hong Kong Legislative Council's approval of the Stablecoin Bill marks a significant regulatory milestone, establishing a comprehensive framework for stablecoins and attracting Web3 projects to the region [4]. Group 5: Future Outlook - Market sentiment indicates confidence in the "innovative drug + stablecoin" integration, with expectations that Huajian Medical's RWA ecosystem could reshape valuation logic in the medical innovation sector [5]. - The potential for the company's stock to continue rising remains a point of interest for investors as it navigates the stablecoin landscape [5].